New Issue: Science’s Impossible Questions. Read Now

Anti-GM Groups Attempt to Sully Transgenic Control of Dengue Fever

Some lab-bred GM mosquitoes can survive in the wild, green groups say, but the bug-maker calls that assertion 'inaccurate'

Join Our Community of Science Lovers!

Genetically engineered mosquitoes developed by British biotech firm Oxitec as an approach to controlling dengue fever have been caught up in controversy since 6,000 of them were deliberately released to an uninhabited forest in Malaysia in a trial in December 2010.

The move took many local people and international observers by surprise. For the most part, the problem was not that the mosquitoes were GM or ineffective—previous trials in the Cayman Islands were very successful. Rather the locals took aim at the lackluster efforts made by Oxitec and the Malayan government to consult and notify the public about the trials (see "GM mosquitoes wipe out dengue fever in trial" and "Letting the bugs out of the bag").

Unsurprisingly anti-GM campaigners went for the company’s jugular over the incident, and have been trying to bring them down since. In the latest thrashing, green groups including GeneWatch and Friends of the Earth say Oxitec tried to hide results showing the GM mosquitoes could survive in the wild (Daily Mail).


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Oxitec engineered the males so that they will die unless they are given the antibiotic tetracycline which is not generally available once they are released into the wild. The green groups obtained a study showing that 15 percent of the offspring of lab-bred GM mosquitoes survived when fed on cat food which contains low levels of tetracycline. Tetracycline can sometimes be found at low levels in the environment. This represents a "failure of the technology," they say.

The green groups have made "inaccurate public assertions" with the purpose of causing "anxiety" about GM technology and its the regulatory process, counters Oxitec. Given how the Daily Mail covered the story, Oxitec has a point.

The green groups' claims have "no substance as they could have known had they asked us about any part of it," Luke Alphey co-founder and chief scientist of Oxitec told Nature.

In further studies Oxitec investigated whether the tetracycline levels that can be found in the environment are likely to lead to survival of our mosquitoes.

“While tetracycline can be found in the environment in isolated areas it is not present in sufficient quantity to ensure survival of the mosquitoes,” the company says.

About two-fifths of the world’s population are at risk of contracting dengue fever. The green groups "risk undermining the chance of a real solution coming to cultures who have a real problem," the company says.

The fight continues.

This post is reproduced with permission from the magazine Nature. The article was first published on January 12, 2012.

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe